Pomerantz Law Firm Reminds Aldeyra Investors of Losses

Investors who suffered losses on their Aldeyra investments are urged to contact the firm.

Apr. 8, 2026 at 12:27am

Got story updates? Submit your updates here. ›

An extreme close-up of complex financial machinery, such as a bank vault door or trading floor computer servers, rendered in high-contrast black and white. The image conveys a sense of the power and complexity of the financial system without using any text or identifiable branding.This lawsuit highlights the risks and potential losses that investors can face when investing in speculative industries like biotech.NYC Today

Pomerantz LLP, a national class action law firm, has announced a class action lawsuit against Aldeyra, a biopharmaceutical company. The lawsuit is on behalf of investors who suffered losses on their Aldeyra investments. Pomerantz is urging these investors to contact the firm to discuss their legal options.

Why it matters

This lawsuit highlights the risks and potential losses that investors can face when investing in speculative biotech companies. It serves as a reminder for investors to thoroughly research companies and understand the potential risks before making investment decisions.

The details

The class action lawsuit against Aldeyra alleges that the company made false and/or misleading statements and/or failed to disclose information pertinent to investors. Pomerantz is representing investors who purchased or otherwise acquired Aldeyra securities between January 1, 2024 and March 31, 2026.

  • The class action lawsuit was announced on April 7, 2026.
  • The lawsuit covers the period from January 1, 2024 to March 31, 2026.

The players

Pomerantz LLP

A national class action law firm representing investors in securities fraud cases.

Aldeyra

A biopharmaceutical company that develops therapies for immune-mediated diseases.

Got photos? Submit your photos here. ›

The takeaway

This lawsuit serves as a reminder for investors to thoroughly research companies and understand the potential risks before making investment decisions, especially in the speculative biotech industry.